Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Clinical Trial

Comparison the Effect of Arbidol Plus Hydroxychloroquine vs Hydroxychloroquine Alone in Treatment of COVID-19 Disease: A Randomized Clinical Trial

Author(s): Rozita Khodashahi, Hamidreza Naderi, Amin Bojdy, Ali Akbar Heydari, Ashraf Tavanaee Sani, Mohammad Javad Ghabouli, Mohammad Reza Sarvghad, Mahboubeh Haddad, Mahnaz Arian, Shahrzad Jahanian, Saeedeh Mazidi, Maziar Mortazavi Pasand, Binyamin Hoseini, Maliheh Dadgarmoghaddam, Ali Khorsand and Mandana Khodashahi*

Volume 16, Issue 4, 2020

Page: [252 - 262] Pages: 11

DOI: 10.2174/1573398X17666210129125703

Price: $65

Abstract

Background and Aim: The main challenging issue about coronavirus disease 2019 (COVID-19) is the production of safe and stable vaccines, which is a very long process. Due to the emergency situation, regular and extensive screening of available and traditional drugs, which are commonly used for the treatment of similar viral diseases, can be a reasonable option. The present study aimed to compare the administration of hydroxychloroquine (HCQ) plus arbidol to the use of HCQ alone in the treatment of COVID-19 infection.

Methods and Materials: This single-blind randomized controlled trial was carried out on a total of 100 patients with COVID-19 referring to the infection ward of Imam Reza Hospital in Mashhad, Iran, in 2020. The patients were randomly assigned to two HCQ alone and HCQ plus arbidol groups.

Results: According to the obtained results, hematological parameters, including white blood cell count, hemoglobin level, lymphocyte count, and platelet count, improved in patients with COVID-19 after the treatment with both HCQ plus arbidol and HCQ alone (P<0.005). The mean values of the reduction time of C-reactive protein (CRP) were 4.48±1.24 and 8.22±2.08 days in the arbidol and HCQ alone groups, respectively, indicating that CRP decreased faster in the arbidol group than that reported for the HCQ alone group (Z=0.-7.85; P<0.000). The mean scores of hospital stay were reported as 5.89±2.04 and 9.35±3.72 days in the arbidol and HCQ alone groups, respectively (Z=-4.31; P<0.005). All the patients in the arbidol group survived, while 6% of the subjects in the HCQ alone group died. In addition, the drug regimen was not changed for any patient, and no subject was transferred to the intensive care unit in the arbidol group.

Conclusion: In summary, the administration of both arbidol and HCQ leads to the improvement of the hematological parameters. The present study introduced arbidol as an effective treatment for moderate to severe patients with COVID-19, which not only reduced the time of CRP normalization level but also decreased the hospitalization duration and mortality compared to those reported for HCQ.

Keywords: COVID-19, hydroxychloroquine, arbidol, umifenovir, viral diseases, emergency situation.

Graphical Abstract
[1]
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020; 92(4): 441-7.
[http://dx.doi.org/10.1002/jmv.25689] [PMID: 31994742]
[2]
Wu P, Hao X, Lau EHY, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill 2020; 25(3) : 2000044.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.3.2000044] [PMID: 31992388]
[3]
COVID-19 CORONAVIRUS PANDEMIC 2020.https://www.worldometers.info/coronavirus/
[4]
Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 2010; 48(8): 2940-7.
[http://dx.doi.org/10.1128/JCM.00636-10] [PMID: 20554810]
[5]
Emery SL, Erdman DD, Bowen MD, et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis 2004; 10(2): 311-6.
[http://dx.doi.org/10.3201/eid1002.030759] [PMID: 15030703]
[6]
Brooks MJ, Burtseva EI, Ellery PJ, et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 2012; 84(1): 170-81.
[http://dx.doi.org/10.1002/jmv.22234] [PMID: 22028179]
[7]
Popov A, Simakova A, Dmitrenko K, Shchelkanov MY. Time course of changes in cytokines (IFN-γ, IFN-α, IL-18, TNF-α) in the treatment of moderate influenza A (H1N1) pdm09 (2013-2016) with oseltamivir (Tamiflu) and umifenovir (Arbidol) alone and in combination with Kagocel. Therapeutic archive 2017; 89(10): 66-70.
[8]
Liu Q, Xiong HR, Lu L, et al. Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacol Sin 2013; 34(8): 1075-83.
[http://dx.doi.org/10.1038/aps.2013.54] [PMID: 23770981]
[9]
DeWald LE, Johnson JC, Gerhardt DM, et al. In vivo activity of Amodiaquine against Ebola Virus Infection. Sci Rep 2019; 9(1): 20199.
[http://dx.doi.org/10.1038/s41598-019-56481-0] [PMID: 31882748]
[10]
Wang Y, Ding Y, Yang C, et al. Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret). Biomed Pharmacother 2017; 91: 393-401.
[http://dx.doi.org/10.1016/j.biopha.2017.04.091] [PMID: 28475918]
[11]
Pshenichnaya NY, Bulgakova V, Lvov N, Poromov A, Selkova E, Grekova A. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR). Therapeutic archive 2019; 91(3): 56-63.
[12]
Shi L, Xiong H, He J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 2007; 152(8): 1447-55.
[http://dx.doi.org/10.1007/s00705-007-0974-5] [PMID: 17497238]
[13]
Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). MedRxiv 2020.
[14]
Nojomi M, Yasin Z, Keyvani H, Makiani MJ, Roham M, Laali A. Effect of arbidol on COVID-19: a randomized controlled trial 2020.
[15]
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature 2020; 579(7798): 270-3.
[16]
Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020; 323(14): 1406-7.
[http://dx.doi.org/10.1001/jama.2020.2565] [PMID: 32083643]
[17]
Lin C, Ding Y, Xie B, et al. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: The value of CT images in the course of the disease. Clin Imaging 2020; 63: 7-9.
[http://dx.doi.org/10.1016/j.clinimag.2020.02.008] [PMID: 32120312]
[18]
Jn W, Shen J. Emphasis and scientific evaluate the role of CT in the diagnosis and treatment of novel coronavirus pneumonia. Dalian Yike Daxue Xuebao 2020; 42(01): 1-4.
[19]
Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020; 368(6498): 1499-504.
[http://dx.doi.org/10.1126/science.abc1560] [PMID: 32358203]
[20]
Vafaei S, Razmi M, Mansoori M, Asadi-Lari M, Madjd Z. Spotlight of Remdesivir in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19). Pandemic 2019.
[21]
Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol 2008; 53(4): 9-13.
[PMID: 18756809]
[22]
Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 2018; 38(8): 653-71.
[http://dx.doi.org/10.1007/s40261-018-0656-y] [PMID: 29737455]
[23]
Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014; 107: 84-94.
[http://dx.doi.org/10.1016/j.antiviral.2014.04.006] [PMID: 24769245]
[24]
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003; 3(11): 722-7.
[http://dx.doi.org/10.1016/S1473-3099(03)00806-5] [PMID: 14592603]
[25]
Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect 2017; 5(1)
[http://dx.doi.org/10.1002/prp2.293] [PMID: 28596841]
[26]
Huang H, Guan L, Yang Y, Le Grange JM, Tang G, Xu Y. Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study 2020.
[27]
Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. MedRxiv 2020.
[28]
Chen J, Ling Y, Xi X, Liu P, Li F, Li T. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chin J Infect Dis 2020; 38(0)
[29]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[30]
Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2(1): 69.
[http://dx.doi.org/10.1186/1743-422X-2-69] [PMID: 16115318]
[31]
Channappanavar R, Perlman S, Eds. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in immunopathology 2017.
[32]
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020; 50(4): 332-4.
[http://dx.doi.org/10.1016/j.medmal.2020.03.007] [PMID: 32243911]
[33]
Bilgir O. Comparison of pre-and post-levothyroxine high-sensitivity c-reactive protein and fetuin-a levels in subclinical hypothyroidism. [online]. 2015, vol. 70, n. 2. Clinics 2015; 70(2) ISSN 1807; 5932: 97-101.
[34]
Warusevitane A, Karunatilake D, Sim J, Smith C, Roffe C. Early diagnosis of pneumonia in severe stroke: clinical features and the diagnostic role of C-reactive protein. PLoS One 2016; 11(3): e0150269.
[http://dx.doi.org/10.1371/journal.pone.0150269] [PMID: 26937636]
[35]
Matsumoto H, Kasai T, Sato A, et al. Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. Heart Vessels 2019; 34(12): 1961-8.
[http://dx.doi.org/10.1007/s00380-019-01435-9] [PMID: 31104078]
[36]
Meng L-B, Yu Z-M, Guo P, et al. Neutrophils and neutrophil-lymphocyte ratio: Inflammatory markers associated with intimal-media thickness of atherosclerosis. Thromb Res 2018; 170: 45-52.
[http://dx.doi.org/10.1016/j.thromres.2018.08.002] [PMID: 30118867]
[37]
Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg 2020; 272(2): 342-51.
[38]
Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol 2020; 92(10): 1733-4.
[http://dx.doi.org/10.1002/jmv.25819] [PMID: 32242950]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy